RBC Positive on Sarepta Therapeutics (SRPT) Into Tomorrow's R&D Day
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/9/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts SRPT Hot Sheet
Price: $17.85 -1.98%
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Rating Summary:
19 Buy, 18 Hold, 6 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 10 | Down: 14 | New: 37
Join SI Premium – FREE
RBC Capital analsyt Brian Abrahams notes the agenda for Sarepta Therapeutics (NASDAQ: SRPT) R&D Day tomorrow was just made available here.
The analsyt continues to like the prospects for microdystrophin data, which will be presented at 9:20am ET.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sarepta Therapeutics (SRPT) PT Lowered to $17 at RBC Capital
- Helen of Troy (HELE) PT Raised to $29 at UBS on Q2 Beat
- QXO Inc (QXO) PT Lowered to $20 at DA Davidson
Create E-mail Alert Related Categories
Analyst Comments, FDA, Trader TalkRelated Entities
RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
